PRESCRIBING PATTERN OF ANTIDIABETIC DRUGS AND ITS ADHERENCE TO AMERICAN DIABETES ASSOCIATION GUIDELINES IN PATIENTS OF TYPE 2 DIABETES MELLITUS WITH AND WITHOUT CO-MORBIDITIES IN RURAL TERTIARY CARE HOSPITAL IN CENTRAL INDIA

SHANTANU SHEKHAR AMIN; SANGITA DEVRAO JOGDAND

doi:10.22159/ajpcr.2025v18i9.55171

Authors

SHANTANU SHEKHAR AMIN Department of Pharmacology, Jawaharlal Nehru Medical College, Sawangi (Meghe), Datta Meghe Institute of Higher Education and Research (Deemed to be University), Maharashtra, India. https://orcid.org/0009-0002-8875-639X
SANGITA DEVRAO JOGDAND Department of Pharmacology, Jawaharlal Nehru Medical College, Sawangi (Meghe), Datta Meghe Institute of Higher Education and Research (Deemed to be University), Maharashtra, India. https://orcid.org/0000-0002-0670-5162

DOI:

https://doi.org/10.22159/ajpcr.2025v18i9.55171

Keywords:

Guidelines, Oral anti-diabetic drugs, Fixed-dose combinations, Rural healthcare, Diabetes

Abstract

Objectives: (1) To assess the prescription patterns of antidiabetic drugs in Type 2 diabetes patients in Rural Central India. (2) To assess compliance with American Diabetes Association guidelines for the management of Type 2 diabetes. (3) To assess the clinical and demographic characteristics, such as age, gender, comorbidities, and lifestyle. (4) To assess glycemic control based on glycated hemoglobin (HbA1c) levels. (5) Determine the most commonly prescribed antidiabetic treatments and drug selection factors.

Methods: A retrospective observational study of 120 patients evaluated demographics, lifestyle characteristics, comorbidities, HbA1c, and prescribed antidiabetic treatments, with emphasis on guideline compliance.

Results: The majority of participants (70.87%) were aged 41–60 years, with a near-equal gender distribution. While 89.17% adhered to lifestyle modifications, 54.17% were overweight, and 12.50% were obese. Risk factors included smoking (35.83%) and alcohol consumption (14.17%). HbA1c levels indicated that 55% had moderate glycemic control (6.5–8), though 16.67% had levels above 10. Common comorbidities included hypertension (45.00%), dyslipidemia (35.00%), and cardiovascular disease (22.50%). The most frequently prescribed antidiabetic therapy was the fixed-dose combination of glimepiride and metformin (54%), with insulin therapy used in 30% of cases. Adherence to American Diabetes Association guidelines was high (90%), though 10% showed non-adherence due to patient refusal or off-guideline practices.

Conclusion: The study underscores the importance of holistic diabetes care, addressing lifestyle, pharmacological, and guideline adherence to improve outcomes.

Downloads

Download data is not yet available.

References

1. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: International Diabetes Federation; 2021.

2. Anjana RM, Deepa M, Pradeepa R, Mahanta J, Narain K, Das HK, et al. Prevalence of diabetes and prediabetes in 15 states of India: Results from the ICMR-INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol. 2017;5(8):585-96. doi: 10.1016/ s2213-8587(17)30174-2, PMID 28601585

3. Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: A review of current evidence. Diabetologia. 2019;62(1):3-16. doi: 10.1007/s00125-018-4711-2, PMID 30171279

4. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102. doi: 10.1016/j.molmet.2020.101102, PMID 33068776

5. American Diabetes Association. Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S1-2. doi: 10.2337/ dc21-sint, PMID 33298409

6. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2018;41(12):2669-701. doi: 10.2337/dci18-0033, PMID 30291106

7. India State-level disease burden initiative diabetes collaborators. The increasing burden of diabetes and variations among the states of India: The global burden of disease study 1990-2016. Lancet Glob Health. 2018;6(12):e1352-62.

8. Ali MK, Singh K, Kondal D, Devarajan R, Patel SA, Shivashankar R, et al. Effectiveness of a multicomponent quality improvement strategy to improve achievement of diabetes care goals: A randomized, controlled trial. Ann Intern Med. 2016;165(6):399-408. doi: 10.7326/ m15-2807, PMID 27398874

9. Joshi SR, Das AK, Vijay VJ, Mohan V. Challenges in diabetes care in India: Sheer numbers, lack of awareness and inadequate control. J Assoc Physicians India. 2008;56:443-50. PMID 18822625

10. Kapur A, Harries AD. The double burden of diabetes and tuberculosis - public health implications. Diabetes Res Clin Pract. 2013;101(1):10-9. doi: 10.1016/j.diabres.2012.12.001, PMID 23305899

11. Cefalu WT, Buse JB, Tuomilehto J, Fleming GA, Ferrannini E, Gerstein HC, et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: A scientific statement from the American heart association and the American Diabetes Association. Diabetes Care. 2019;42(8):1486-523.

12. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-53. doi: 10.2337/diacare.27.5.1047, PMID 15111519

13. Kalra S, Gupta Y. Epidemiology of type 2 diabetes mellitus in India: Real-world insights. Int J Diabetes Dev Ctries. 2020;40(1):1-5.

14. Das AK, Seshiah V, Sahay RK, Kumar A, Asirvatham AJ, Balaji V, et al. Evidence-based management of type 2 diabetes: Indian guidelines. J Assoc Physicians India. 2009;57 Suppl:1-56.

15. Anjana RM, Pradeepa R, Deepa M, Datta M, Sudha V, UnnikrishnanR, et al. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in Urban and Rural India: Phase I results of the Indian Council of Medical Research-India Diabetes (ICMR-INDIAB) study. Diabetologia. 2011;54(12):3022-7. doi: 10.1007/s00125-011-2291-5, PMID 21959957

16. Tripathy JP, Thakur JS, Jeet G, Chawla S, Jain S, Pal A, et al. Prevalence and risk factors of diabetes in a large community-based study in North India: Results from a steps survey in Punjab, India. Diabetol Metab Syndr. 2017;9:8. doi: 10.1186/s13098-017-0207-3, PMID 28127405

17. Pradeepa R, Anjana RM, Joshi SR, Bhansali A, Deepa M, Joshi PP, et al. Prevalence of generalized and abdominal obesity in Urban and Rural India--the ICMR-INDIAB study (Phase-I) [ICMR - NDIAB-3]. Indian J Med Res. 2015;142(2):139-50. doi: 10.4103/0971-5916.164234, PMID 26354211

18. Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab. 2008;93(11 Suppl 1):S9-30. doi: 10.1210/jc.2008-1595, PMID 18987276

19. Samanta S, Paul P, Ghosh K. Drug-related problems among T2DM patients with hypertension: Association with smoking and alcohol. Int J Pharm Pharm Sci. 2025;17(2):213-8. doi: 10.22159/ ijpps.2025v17i2.50297

20. Najeeb S, Bindu P, Thomas J. Determinants of glycemic control in Ernakulam, Kerala: Medication adherence and lifestyle factors. Int J Appl Pharm. 2024;16(3):45-52.

21. Shukla H, Ramesh S, Iyer S. Empagliflozin added to standard T2DM therapy in rural India: Glycemic and weight outcomes. Int J Curr Pharm Rev Res. 2025;17(1):78-84.